Abstract:Objective Hyperphenylalaninemia (HPA) is a genetic disease with the higher blood phenylalanine (Phe) level caused by the phenylalanine hydroxylase deficiency or the lower enzyme activity. Phenylketonuria (PKU) is the most common type of HPA. In this paper, the authors reviewed the clinical diagnosis, treatment and gene mutation detection of HPA in order to set up a preventive and therapeutic method for the disease. Method Seven hundred and sixty-nine subjects (454 males and 315 females, aged 0.8—27 years) with HPA from 28 provinces of China were enrolled in this study. Among them, 95 patients were diagnosed by the neonatal screening, 50 diagnosed by the high risk screening, the other 624 patients were diagnosed later. The family histories of all patients were investigated. The Phe concentration was determined with Guthrie bacterial inhibition assay and fluorescence method. The tetrahydrobiopterin deficiency (BH4D) was examined with the urinay pterin analysis and BH4 loading test. PKU patients were treated with the low or free Phe formula. The patients with BH4D were treated with BH4 and neurotransmitter precursors. The effects of the clinical treatment in patients with various HPA types were evaluated. The PKU gene was detected for mutations in 100 PKU patients. Prenatal diagnosis was carried out for 23 families with high risk PKU by using denaturing gradient gel electrophoresis (DGGE) and STR linkage analysis. Result (1) Of 769 patients 730 were diagnosed as having classic PKU, 27 patients as mild HPA and, 12 patients as BH4D whose urinary percentage of biopterin was (1.74±2.6) %, which was below the normal range. (2) Three hundred and thirty-eight PKU cases were treated with low or no phenylalanine milk. Of 95 patients, 71.6% of patients was diagnosed by neontal screening and 54.7% of 243 patients diagnosed later and the Phe could be better controlled with the treatment. (3) The intelligence quotient (IQ) evaluation was performed in 112 treated patients. The IQ of 55 patients diagnosed and treated after the neonatal screening was (78±22) score, IQ of 57 patients diagnosed later was (62±18) score. The IQ scores of these two groups were significantly different(P<0.001). IQ score of five BH4D patients was 70—80 after the treatment with combination of BH4 and neurotransmitter precursors. (4) Seventy-two patients went to school and 66.7% of them showed a middle or higher study score. (5) Five mutations, Arg111Ter, Arg241Cys, Arg243Glu, IVS6nt-1 and Arg252Gln, as well as a polymorphism of Val245Val were found in 100 PKU cases. (6)Prenatal diagnosis was performed for 23 families with high risk PKU, three fetuses were found to have PKU, and 20 fetuses were normal or heterozygotes which was confirmed by the neonatal screening for PKU after birth. Conclusion Both prenatal diagnosis and early diagnosis are effective methods for prevention and treatment of PKU. The early treatment and restriction of Phe level can minimize the mental retardation for HPA patients. Key words: Phenylketonurias; Neonatal screening; Biopterin; Genes; Mutation

Comparative study on secondary seizure to tetrahydrobiopterin and phenylketonuria

Pitfalls in the Management of Phenylketonuria in China

Delayed Brain Myelination in Children with Phenylketonuria Complicated with Epilepsia

Efficacy and Safety of a Phenylalanine-Free Amino Acid-Based Enteral Formula (AA-PKU2) in 1-8 Year-Old Children with Phenylketonuria: a Prospective, Open, Self-Controlled and Multi-Center Study in China

The Behavioral and Emotional Problems of Patients with Phenylketonuria Early Treated with Dietotherapy

[An Eighteen-Year Study on Phenylketonuria].

Analysis of Phenylketonuria in 39 Children

Mental and motor development and psychosocial adjustment of Chinese children with phenylketonuria.

A case report of adult phenylketonuria and literature review

[Psychomotor Retardation and Intermitent Convulsions for 8 Months in an Infant].

Study on brain delayed myelination and blood phenylalanine of patients with phenylketonuria

Characterisation and differential diagnosis of neurological complications in adults with phenylketonuria: literature review and expert opinion

Malignant Phenylketonuria Presented with Paroxysmal Movement Disorders: Report of One Case and Review of the Literature

Application of tetrahydrobiopterin in treatment of phenylketonuria

Diagnosis, Treatment and Gene Detection in 769 Cases with Hyperphenylalaninemia

Effect of Delayed Diagnosis of Phenylketonuria With Imaging Findings of Bilateral Diffuse Symmetric White Matter Lesions: A Case Report and Literature Review

Advances in research of molecular mechanism of phenylketonuria and its treatments

Studies on neonatal screening, clinical and gene analysis for tetrahydrobiopterin deficiency in Southern Chinese

Clinical and Genetic Features in Pyridoxine‐dependent Epilepsy: a Chinese Cohort Study

Demographics, diagnosis and treatment of 256 patients with tetrahydrobiopterin deficiency in mainland China: results of a retrospective, multicentre study

Clinic studies on the different type of tetrahydrobiopterin responsive phenylalanine hydroxylase deficiency